Most multiple sclerosis patients who try Bayer’s BETACONNECT auto-injector stick with their treatment, a study reports.
The electronic product may overcome the problem of many patients failing to stick to a therapy ... Read more
The U.S. Food and Drug Administration has approved a supplemental biologics license application for two Bayer products that help multiple sclerosis patients keep track of their injections of Betaseron (interferon beta-1b). The products ... Read more
The U.S. Food and Drug Administration (FDA) has accepted Bayer’s filing of a supplemental biologics license application (sBLA) for two products designed to improve the lives of people with multiple ... Read more
Treating relapsing and remitting forms of multiple sclerosis requires a combination of cognitive and behavioral therapies, physiotherapy, lifestyle changes, and medication. Several pharmaceutical companies have clinical development plans in ... Read more
Global pharma Bayer Healthcare aims to improve human health by diagnosing, preventing, and treating a variety of diseases. The company currently provides products for general medicine, hematology, neurology, oncology, and women’s healthcare. ... Read more
Bayer HealthCare is pleased to announce the US Food and Drug Administration (FDA) has granted the approval of BETACONNECT, a first-of-its-kind electronic autoinjector indicated as a treatment for relapsing-remitting multiple sclerosis ... Read more
Bayer HealthCare recently announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a supplemental Biologics License Application (sBLA) for BETACONNECT for the treatment of relapsing-remitting multiple ... Read more